Synermore Biologics (suzhou) Co., Ltd.
Clinical trials sponsored by Synermore Biologics (suzhou) Co., Ltd., explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New antibody combo could shield kids from rabies after bites Results expected Oct 2026 (estimated)
-
Experimental antibody cocktail offers hope for rabies patients with no other options
Disease control Expanded accessThis program provides access to SYN023, a combination of two lab-made antibodies (zamerovimab and mazorelvimab) designed to neutralize the rabies virus. It is for people in the United States with confirmed or suspected life-threatening rabies who cannot join other studies or acce…
Sponsor: Synermore Biologics (Suzhou) Co., Ltd. • Aim: Disease control
Last updated Jul 19, 2026 00:00 UTC
-
New antibody combo could shield kids from rabies after bites
Prevention Recruiting nowThis study follows 232 children under 18 who received a new antibody injection (zamerovimab and mazorelvimab) plus the rabies vaccine after a severe animal bite. Researchers track whether the children stay rabies-free for up to one year. The goal is to see if this combination pre…
Sponsor: Synermore Biologics (Suzhou) Co., Ltd. • Aim: Prevention
Last updated Jun 27, 2026 12:23 UTC